Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Ardana Bioscience Ltd.

Home Clinical Trial Sponsors and OrganizationsArdana Bioscience Ltd.

Ardana Bioscience Ltd.

CLOSED

United Kingdomwww.ardana.co.ukPrivate11–50 employeesEstablished: 2000-01-01

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

11

8 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

2000

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 3

2

18.2%

Phase 2

1

9.1%

Trial Status Distribution

Active, not recruiting

8

72.7%

Completed

2

18.2%

Terminated

1

9.1%

Clinical Trials

Trials sponsored by this organization (11)

Open-Label Study of ARD-0403 in Testosterone Deficient Men

Oct 2007150 participants

A Phase II multi-centre, open-label study investigating the long-term safety and efficacy of Teverelix, long-acting formulation in patients with advanced prostate cancer – follow on study to Study N°. ARD-0301-004

Active, not recruiting

Sep 200733 participants

A Phase II multi-centre, open-label study investigating the long-term safety and efficacy of Teverelix, long-acting formulation in patients with advanced prostate cancer – follow on study to Study N°. ARD-0301-004

Active, not recruiting

Aug 200733 participants

Open-Label Study of ARD-0403 in Testosterone Deficient Men

May 2007150 participants

A Phase II multi-centre, open-label study investigating the efficacy and safety of a new GnRH antagonist, Teverelix, long-acting formulation in patients with advanced prostate cancer

Active, not recruiting

Feb 200754 participants

A Phase II multi-centre, open-label study investigating the efficacy and safety of a new GnRH antagonist, Teverelix, long-acting formulation in patients with advanced prostate cancer

Active, not recruiting

Feb 200740 participants

A Phase II multi-centre, randomized, open-label study investigating the pharmacokinetics, pharmacodynamics, efficacy and safety of two loading dose regimens of a new GnRH antagonist, Teverelix, long-acting formulation administered subcutaneously as three doses of 120 mg or 180 mg (given as 2 injections of 60 mg or 90 mg on Day 1, repeated on Days 2 & 3) in patients with advanced prostate cancer

Active, not recruiting

Sep 200640 participants

A Phase II multi-centre, randomized, open-label study investigating the pharmacokinetics, pharmacodynamics, efficacy and safety of two loading dose regimens of a new GnRH antagonist, Teverelix, long-acting formulation administered subcutaneously as three doses of 120 mg or 180 mg (given as 2 injections of 60 mg or 90 mg on Day 1, repeated on Days 2 & 3) in patients with advanced prostate cancer

Active, not recruiting

Sep 200652 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials11
Approvals
News

Back to Organizations